

Management of Ethanol Withdrawal



Ethanol

Mechanisms of Action

- Stimulates GABA → downregulates receptor
- Inhibits NMDA → upregulates receptor
- Result in chronic use = excitatory state

Ethanol Withdrawal Symptoms

Timing of alcohol withdrawal syndromes

Syndrome	Clinical findings	Onset after last drink
Minor withdrawal	Tremulousness, mild anxiety, headache, diaphoresis, palpitations, anorexia, GI upset; Normal mental status	6 to 36 hours
Seizures	Single or brief flurry of generalized, tonic-clonic seizures, short post-ictal period; Status epilepticus rare	6 to 48 hours
Alcoholic hallucinosis	Visual, auditory, and/or tactile hallucinations with intact orientation and normal vital signs	12 to 48 hours
Delirium tremens	Delirium, agitation, tachycardia, hypertension, fever, diaphoresis	48 to 96 hours

Ethanol Withdrawal

Management Principles

- alcohol withdrawal → seizures → DTs
- why in withdrawal? (\$, GIB, AKA)
- address/treat other medical conditions
- administer thiamine
- medication
- if in DT's → admit to ICU, not easily reversible

Benzodiazepines

- current “mainstay”
 - mechanism: GABA_A agonists
- benefits
 - wide safety margin
 - anticonvulsant properties
 - no ceiling dose
 - practitioner comfort
 - *effective*

Benzodiazepines

Benzodiazepines for AWS [5,6,8].

Drug	Time to onset	Active metabolites?	Half-life (hrs)	Initial dose
Diazepam	1–5 min IV	Yes	43 ± 13	10–20 mg IV 10–20 mg PO
Lorazepam	5–20 min IV	No	14 ± 5	2–4 mg IV 2–4 mg PO
Midazolam	2–5 min IM/ IV	Yes	2 ± 1	2–4 mg IM/IV
Oxazepam	2–3 h PO	No	8 ± 2	15–30 mg PO every 8 h
Chlordiazepoxide	2–3 h PO	Yes	10 ± 3	50–100 mg PO

Benzodiazepines

Disadvantages

- do not agonize NMDA
- respiratory depression
 - despite continued withdrawal
- need for additional adjuncts

Phenobarbital

- stimulates NMDA + GABA_A
- predictable peak CNS effect (20-30 minutes)
- relatively cheap
- no ceiling dose
- 3-4 days duration → no DC meds

Phenobarbital

Disadvantages

- practitioner unfamiliarity
 - Example: status epilepticus 20 mg/kg load
- Sharp ED → not in pyxis (yet)
so takes 30-60 minutes to get from inpatient pharmacy



Phenobarbital + Benzos

Evidence

- intervention:
 - 10mg/kg IV phenobarbital + lorazepam CIWA
 - placebo + lorazepam CIWA
- results:
 - fewer ICU admissions (8% vs 25%)
 - no difference adverse events
 - decreased total lorazepam (26 mg vs 49 mg)

Rosenson et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. *J Emerg Med* 2013;44:592-8

Phenobarbital + Benzos

Evidence

- barbs alone or in combination with benzos
 - at least as effective
 - acceptable tolerability, safety
- adding phenobarbital to benzos reasonable
 - particularly to benzo-refractory pts

J Critical Care 2016; 32: 101-7



Phenobarbital

UCSD Proposed Dosing-conservative

- mild- 3 mg/kg
 - no response → repeat same dose
 - partial response → 1.5 mg/kg
- moderate/severe- 5 mg/kg
 - no response → repeat same dose
 - partial response → 3 mg/kg
- DT's 10 mg/kg
 - no response → repeat same dose
 - partial response → 5 mg/kg

*Round up to vial size

*Ideal body weight or adjusted body weight

Use of Phenobarbital

- Average sized adult: 260mg IVPB
- Timing
 - wait 30 minutes prior to re-dosing (130mg increments)
- treatment goal
 - mild sedation, normalization of vitals
- serial dosing
 - can always add more

Ethanol Withdrawal Treatment Summary

	Phenobarbital	Benzodiazepines
Receptors	GABA, NMDA	GABA
Half life	Long (3-4Days)	Hours (variable)
DC meds req'd	No	Yes

Ketamine

- potential benefits:
 - NMDA antagonist
 - shorter acting so can give as infusion
 - maintenance of airway/breathing

Wong et al. Evaluation of adjunctive ketamine to benzodiazepines for management alcohol withdrawal syndrome. *Ann Pharmacother* 2015;49: 14-19 (0.3 mg/kg load; mg/kg/hr)

Shah et al. Adjunctive use of ketamine for benzodiazepine-resistant severe alcohol withdrawal: a retrospective evaluation. *J Med Tox* 2018;14: 229-36 (median initial 0.75mg/kg/hr)



Ketamine in Delirium Tremens

- retrospective (total 63 patients)
- adjunct to benzos
- intervention:
 - potential bolus 0.3 mg/kg
 - infusion 0.15-0.3 mg/kg/hr
- endpoint: delirium resolution

Pizon et al. Adjunct ketamine use in the management of severe ethanol withdrawal. *Crit Care Med* 2018; 46: e768-71

TABLE 2. Outcomes in Patients With Severe Ethanol Withdrawal Who Receive No Ketamine Versus Ketamine

Outcomes	No Ketamine (<i>n</i> = 29)	Ketamine (<i>n</i> = 34)	<i>p</i>
Mean ICU days	11.2	5.7	<0.001
Mean hospital days	16.6	12.5	0.03
Mean benzodiazepine dose in DE, mg	2,525.1	1,508.5	0.02
Dexmedetomidine use, <i>n</i>	3	9	0.1
Mean dexmedetomidine time, d	2.33	1.77	0.4
Intubations, <i>n</i>	22	10	<0.001
Mean benzodiazepine dose in DE equivalents, mg	3,016.1	833.6	0.01
Propofol use, <i>n</i>			0.9
Mean propofol time, d	4.57	2.4	0.03

DE — diazepam equivalents.

Ethanol Withdrawal Treatment

- Phenobarbital is safe +/- benzodiazepines
- Phenobarbital dosing:
 - 260mg IVPB
 - Wait at least 30 min for peak CNS effect
 - May repeat in 130mg increments (or use UCSD protocol 3-10mg/kg)
- If patient is discharged → no further medications required
- ICU for DTs → consider ketamine infusion +GABA agonist